{"entity":{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Apalutamide in prostate cancer, run by Janssen Pharmaceutica N.V., Belgium, active and no longer recruiting.","summary":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer is a phase 3 interventional study registered as NCT04557059 by Janssen Pharmaceutica N.V., Belgium, with 691 participants enrolled, started 2020-11-12 and due to reach its primary completion in 2029-08-27. Interventions recorded: Radiotherapy, LHRHa and Apalutamide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04557059","url":"https://clinicaltrials.gov/study/NCT04557059"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["apalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04557059","phase":"3","setting":"A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort","sponsor":"Janssen Pharmaceutica N.V., Belgium","enrolled":691,"outcomes":[]},"route":"/trials/nct04557059/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/"}]}}